Email Us
Call Us
AUSTIN, Texas – January 25, 2015 – Altogen Labs today detailed its protein overexpression stable cell line development service, delivering mammalian lines that stably express a target protein of interest in 28 days.
Overexpression lines are foundational infrastructure for several categories of program. Recombinant antibody production requires cells presenting the antigen. Drug screening against a specific receptor requires a line expressing that receptor at consistent levels. Gene function studies require a controlled gain-of-function comparison against the parental line. In each case the quality of the engineered line determines the quality of everything downstream.
Altogen Labs generates lines stably overexpressing a protein of interest, alongside stable RNAi knockdown lines and tetracycline-inducible knockdown systems, in the cell background the sponsor specifies. The 28-day timeline is one of the faster available from an independent CRO, and reflects the company’s cell culture expertise across more than 100 cell lines.
Validation is performed in-house: mRNA expression confirmed by qRT-PCR and protein expression confirmed by automated capillary Western with normalization to total protein. Completed lines are cryopreserved and can be banked as GLP-compliant master and working cell banks for the life of the program.
Engineered lines can move directly into the company’s validated in vivo models, allowing a target’s role in tumor growth to be tested in an animal using the same material characterized in culture. One hundred percent of intellectual property belongs to the client.
About Altogen Labs
Altogen Labs is a preclinical CRO supporting drug development programs across oncology, pharmacology, toxicology, and translational research. The company has extensive experience with xenograft tumor models for preclinical efficacy studies and in vivo toxicology for safety evaluation, with a strong emphasis on high-quality, reproducible study execution and full client ownership of project-specific intellectual property. Altogen Labs works with pharmaceutical, biotechnology, and academic organizations worldwide to evaluate therapeutic candidates in validated in vivo models and generate data for efficacy, safety, PK/PD, pathology, and IND-supporting studies. The company provides integrated preclinical services from early-stage evaluation through advanced development.
Contact Information:
Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com